The Role of Tumour Metabolism in Cisplatin Resistance.
DNA damage repair
ROS
cisplatin
resistance
tumour metabolism
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
04
2021
accepted:
10
06
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Cisplatin is a chemotherapy drug commonly used in cancer treatment. Tumour cells are more sensitive to cisplatin than normal cells. Cisplatin exerts an antitumour effect by interfering with DNA replication and transcription processes. However, the drug-resistance properties of tumour cells often cause loss of cisplatin efficacy and failure of chemotherapy, leading to tumour progression. Owing to the large amounts of energy and compounds required by tumour cells, metabolic reprogramming plays an important part in the occurrence and development of tumours. The interplay between DNA damage repair and metabolism also has an effect on cisplatin resistance; the molecular changes to glucose metabolism, amino acid metabolism, lipid metabolism, and other metabolic pathways affect the cisplatin resistance of tumour cells. Here, we review the mechanism of action of cisplatin, the mechanism of resistance to cisplatin, the role of metabolic remodelling in tumorigenesis and development, and the effects of common metabolic pathways on cisplatin resistance.
Identifiants
pubmed: 34250022
doi: 10.3389/fmolb.2021.691795
pii: 691795
pmc: PMC8261055
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
691795Informations de copyright
Copyright © 2021 Wang, Zhao, Fu, Xu and Yuan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Lymphoma. 2018 Aug;59(8):1797-1806
pubmed: 29045165
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50
pubmed: 25053359
J Transl Med. 2015 May 07;13:146
pubmed: 25947066
Int J Mol Sci. 2020 Jan 31;21(3):
pubmed: 32023830
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Pharmacol Ther. 2012 Oct;136(1):35-55
pubmed: 22796517
Mol Cancer Res. 2020 Jan;18(1):105-117
pubmed: 31628200
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):413-421
pubmed: 29883801
Lancet. 1992 Aug 8;340(8815):329-33
pubmed: 1353804
Chem Res Toxicol. 2017 Apr 17;30(4):980-995
pubmed: 28282121
Cancer Discov. 2015 Jun;5(6):652-67
pubmed: 25829424
J Mol Med (Berl). 2011 Mar;89(3):229-36
pubmed: 21301794
J Cell Biol. 2016 Aug 1;214(3):249-57
pubmed: 27458133
EMBO J. 1995 Nov 15;14(22):5579-88
pubmed: 8521815
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
Lancet Oncol. 2015 Apr;16(4):436-46
pubmed: 25795409
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):51-66
pubmed: 29959989
Mol Pharmacol. 2006 Oct;70(4):1390-4
pubmed: 16847145
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Life Sci. 2019 Sep 1;232:116679
pubmed: 31340168
J Biol Chem. 1974 Aug 25;249(16):5070-9
pubmed: 4605420
Development. 2017 Feb 15;144(4):541-551
pubmed: 28196802
Cell Mol Life Sci. 2016 Jan;73(2):377-92
pubmed: 26499846
J Invest Dermatol. 2003 Jul;121(1):172-6
pubmed: 12839578
Trends Cancer. 2017 Mar;3(3):169-180
pubmed: 28393116
Oncol Lett. 2019 Sep;18(3):2819-2824
pubmed: 31452760
Mol Cell Biol. 2002 Aug;22(16):5793-800
pubmed: 12138190
Nucleic Acids Res. 2005 May 04;33(8):2531-9
pubmed: 15872216
Cancer Commun (Lond). 2018 May 21;38(1):27
pubmed: 29784041
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1498-505
pubmed: 17126209
J Clin Oncol. 2004 May 1;22(9):1598-604
pubmed: 15117981
EMBO J. 2018 Jul 13;37(14):
pubmed: 29875130
J Biol Chem. 2012 Jul 13;287(29):24263-72
pubmed: 22621925
Cancer Cell. 2018 Aug 13;34(2):315-330.e7
pubmed: 30033091
Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
pubmed: 17380161
J Clin Oncol. 1990 Sep;8(9):1556-62
pubmed: 2167953
Front Physiol. 2014 Sep 18;5:358
pubmed: 25278906
Sci Rep. 2018 Mar 6;8(1):4067
pubmed: 29511244
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Int J Clin Exp Med. 2014 Sep 15;7(9):2530-40
pubmed: 25356106
Oral Oncol. 2018 Dec;87:49-57
pubmed: 30527243
BMC Cancer. 2017 Jan 5;17(1):10
pubmed: 28056859
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
J Clin Oncol. 1998 Jul;16(7):2500-4
pubmed: 9667270
Immunity. 2015 Sep 15;43(3):435-49
pubmed: 26377897
Biosci Rep. 2019 May 14;39(5):
pubmed: 30988063
Cell Death Dis. 2014 May 29;5:e1257
pubmed: 24874729
Amino Acids. 2009 May;37(1):1-17
pubmed: 19301095
J Pathol. 2013 Aug;230(4):350-5
pubmed: 23729358
Oncologist. 2000;5(6):471-6
pubmed: 11110598
Bull Cancer. 2017 Feb;104(2):167-176
pubmed: 27989629
J Clin Oncol. 2015 Dec 10;33(35):4219-26
pubmed: 26503202
Cell Oncol (Dordr). 2016 Dec;39(6):511-522
pubmed: 27473273
J Clin Oncol. 2015 Jul 1;33(19):2129-35
pubmed: 25732161
J Clin Oncol. 1996 Mar;14(3):806-13
pubmed: 8622028
Cancer Treat Rev. 1979 Mar;6(1):17-39
pubmed: 378370
Cancers (Basel). 2019 Jun 11;11(6):
pubmed: 31212591
Int J Oncol. 2018 Sep;53(3):1055-1068
pubmed: 30015875
Eur J Pharm Sci. 2015 Jul 10;74:95-102
pubmed: 25930121
Cell Death Dis. 2019 Dec 9;10(12):936
pubmed: 31819048
Cell Res. 2008 Jan;18(1):64-72
pubmed: 18166981
BMB Rep. 2018 Sep;51(9):474-479
pubmed: 30103844
J Biol Chem. 1967 Mar 25;242(6):1347-52
pubmed: 5337590
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Cancer Lett. 2014 Jun 1;347(2):159-66
pubmed: 24657660
Cancer Treat Rev. 2020 Aug;88:102054
pubmed: 32593915
Theranostics. 2019 Aug 12;9(20):5739-5754
pubmed: 31534516
J Biol Chem. 2003 Mar 14;278(11):9100-6
pubmed: 12509415
J Clin Oncol. 1997 Apr;15(4):1427-31
pubmed: 9193335
Cancer Res. 2000 Oct 1;60(19):5390-4
pubmed: 11034077
J Clin Oncol. 2012 Jan 20;30(3):268-73
pubmed: 22184384
Nat Rev Cancer. 2016 Oct;16(10):635-49
pubmed: 27634447
Mol Cell. 2017 Jul 20;67(2):252-265.e6
pubmed: 28689661
Int J Biochem Cell Biol. 2018 Feb;95:9-16
pubmed: 29247711
Theranostics. 2019 May 9;9(10):2999-3013
pubmed: 31244938
Mol Syst Biol. 2013 Dec 03;9:712
pubmed: 24301801
Nat Genet. 2015 Dec;47(12):1475-81
pubmed: 26482881
Onco Targets Ther. 2018 May 25;11:3101-3110
pubmed: 29872321
Cancer Lett. 2016 Feb 1;371(1):20-9
pubmed: 26607904
Nat Rev Cancer. 2012 Jan 12;12(2):133-43
pubmed: 22237392
J Clin Oncol. 1993 Nov;11(11):2150-7
pubmed: 8229129
BMC Cancer. 2018 Jun 5;18(1):636
pubmed: 29866066
Cancer Sci. 2019 May;110(5):1705-1714
pubmed: 30861255
Nat Commun. 2015 Sep 24;6:8468
pubmed: 26399441
Oxid Med Cell Longev. 2019 Nov 14;2019:8201079
pubmed: 31827705
J Clin Oncol. 1997 Jul;15(7):2559-63
pubmed: 9215825
EBioMedicine. 2015 May 23;2(6):478-9
pubmed: 26288805
Sci Rep. 2017 Apr 05;7:45983
pubmed: 28378811
Iowa Orthop J. 2006;26:154-8
pubmed: 16789469
Biomed Res Int. 2018 Nov 12;2018:1736738
pubmed: 30539004
Nature. 1965 Feb 13;205:698-9
pubmed: 14287410
Biomaterials. 2018 Nov;183:77-92
pubmed: 30149232
Acta Pol Pharm. 2014 Nov-Dec;71(6):1060-5
pubmed: 25745780
Int J Cancer. 2007 Jan 1;120(1):175-80
pubmed: 17044026
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302
pubmed: 10944550
Int J Oncol. 2017 May;50(5):1848-1856
pubmed: 28393220
J Cell Biochem. 2018 Jul;119(7):6136-6145
pubmed: 29633308
Nat Commun. 2016 Dec 14;7:13666
pubmed: 27966532
Asian Pac J Cancer Prev. 2014;15(7):3219-26
pubmed: 24815474
Am J Cancer Res. 2018 May 01;8(5):778-791
pubmed: 29888102
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Int Rev Neurobiol. 2019;145:211-238
pubmed: 31208525
J Cell Physiol. 2019 May;234(5):6361-6370
pubmed: 30229902
Mol Pharm. 2018 Aug 6;15(8):3032-3045
pubmed: 29939755
Oncotarget. 2016 Jul 5;7(27):41637-41649
pubmed: 27191653
Cancer Res. 2007 Apr 1;67(7):3364-70
pubmed: 17409446
Front Pharmacol. 2018 Jan 31;9:43
pubmed: 29445340
J Biol Chem. 1994 Jan 14;269(2):787-90
pubmed: 8288625
Chem Rev. 2019 Jan 23;119(2):1519-1624
pubmed: 30489072
Metabolism. 2014 Jul;63(7):895-902
pubmed: 24814684
Mol Pharmacol. 2001 Apr;59(4):657-63
pubmed: 11259608
Cancers (Basel). 2020 Aug 12;12(8):
pubmed: 32806533
N Engl J Med. 1996 Jan 4;334(1):1-6
pubmed: 7494563
Onco Targets Ther. 2020 May 29;13:4833-4842
pubmed: 32581546
Exp Cell Res. 2014 Nov 15;329(1):69-77
pubmed: 25278484
Clin Cancer Res. 2013 Jul 15;19(14):3936-43
pubmed: 23743568
Cell Rep. 2014 May 22;7(4):1248-58
pubmed: 24813884
Oncogene. 1998 Dec 24;17(25):3237-45
pubmed: 9916986
Nucleic Acids Res. 2015 Feb 27;43(4):2466-85
pubmed: 25628363
Front Cell Dev Biol. 2021 Jan 12;8:603837
pubmed: 33511116
Ann Oncol. 2014 May;25(5):987-91
pubmed: 24595454
Oncotarget. 2017 Jul 18;8(29):47691-47708
pubmed: 28548950
Expert Opin Ther Targets. 2019 Jun;23(6):473-483
pubmed: 31076001
J Exp Clin Cancer Res. 2015 Oct 06;34:111
pubmed: 26445347
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Cell Death Differ. 2003 Jul;10(7):808-22
pubmed: 12815464
J Nutr. 2002 Aug;132(8 Suppl):2333S-2335S
pubmed: 12163687
World J Clin Oncol. 2016 Feb 10;7(1):106-13
pubmed: 26862494
Metallomics. 2016 Nov 9;8(11):1170-1176
pubmed: 27722429
In Vivo. 2006 Sep-Oct;20(5):587-9
pubmed: 17091764
Ann Oncol. 2018 Aug 1;29(8):1741-1747
pubmed: 29905759
J Cell Biochem. 2019 Nov;120(11):18714-18723
pubmed: 31218757
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
J Cancer Res Ther. 2018 Sep;14(Supplement):S609-S615
pubmed: 30249876
Anticancer Agents Med Chem. 2016;16(9):1085-92
pubmed: 27025656
Clin Adv Hematol Oncol. 2017 May;15(5):386-396
pubmed: 28591093